Spyre Therapeutics officer proposes $2.61M share sale

The notice also lists two earlier 10b5-1 sales by the officer, dated September 1 and September 2, 2026.

Rhea-AI Filing Summary

Spyre Therapeutics, Inc. (SYRE) reports that officer Heidy King-Jones proposes to sell 29,335 common shares, with an aggregate market value of $2,611,695.05, through Morgan Stanley Smith Barney LLC. The notice identifies October 1, 2026, as the approximate sale date and says the shares were and will be received through stock-option exercises over the next three months; acquisition and payment dates were and will be the dates of exercise and sale.

It also lists prior 10b5-1 sales by Heidy M. King-Jones during the past three months: 400 common shares on September 2, 2026, for $36,000.00, and 27,999 common shares on September 1, 2026, for $2,444,477.89.

Key Figures

Common shares proposed for sale: 29,335 shares Aggregate market value: $2,611,695.05 Prior common shares sold: 400 shares +3 more

6 metrics

Common shares proposed for sale 29,335 shares Approximate sale date October 1, 2026

Aggregate market value $2,611,695.05 Common shares proposed for sale

Prior common shares sold 400 shares September 2, 2026, in the past-three-month sales list

Prior sale value $36,000.00 Sale listed for September 2, 2026

Prior common shares sold 27,999 shares September 1, 2026, in the past-three-month sales list

Prior sale value $2,444,477.89 Sale listed for September 1, 2026

Key Terms

Rule 144, 10b5-1, stock options, aggregate market value

4 terms

Rule 144 regulatory

"the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

10b5-1 regulatory

"10b5-1 Sales for HEIDY M KING-JONES"

A 10b5-1 plan is a pre-set schedule that lets company insiders buy or sell shares according to written instructions made when they do not possess material, nonpublic information. Think of it as a timed automatic payment for stock trades: it helps insiders avoid accusations of trading on secret information and gives outside investors a clearer signal about whether sales are routine or potentially informative about the company’s prospects.

stock options financial

"received upon the exercise of stock options"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

aggregate market value financial

"29335 | 2611695.05"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many SYRE shares does Heidy King-Jones plan to sell?

Heidy King-Jones, an officer of Spyre Therapeutics, Inc., listed 29,335 common shares for sale, with an aggregate market value of $2,611,695.05. The notice identifies October 1, 2026, as the approximate sale date.

What prior SYRE sales did Heidy King-Jones report?

The notice lists prior 10b5-1 sales of 400 common shares for $36,000.00 on September 2, 2026, and 27,999 common shares for $2,444,477.89 on September 1, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/01/2026 - 04:31 PM Accepted by SEC EDGAR 10/01/2026 - 04:30 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001794898
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	SPYRE THERAPEUTICS, INC.
SEC File Number	001-37722
Address of Issuer	221 Crescent Street Building 23 Suite 105 Waltham MASSACHUSETTS 02453
Phone	6176515940
Name of Person for Whose Account the Securities are To Be Sold	HEIDY KING-JONES
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	29335	2611695.05	88173762	10/01/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/01/2026	Exercise of Stock Options	Issuer			29335	10/01/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for HEIDY M KING-JONES 221 Crescent Street Building 23 Suite 105 Waltham MA 02453	Common	09/02/2026	400	36000.00
10b5-1 Sales for HEIDY M KING-JONES 221 Crescent Street Building 23 Suite 105 Waltham MA 02453	Common	09/01/2026	27999	2444477.89

144: Remarks and Signature

Remarks	The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.
Date of Notice	10/01/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	04/16/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Heidy King-Jones
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)